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Objective: To describe the changes in costs of care for HIV-positive patients in Italy after the spread of antiretroviral combination
therapies (HAART).
Methods: Five thousand four hundred and twenty-two patients from the I.CO.N.A. (Italian Cohort Naive Antiretrovirals) study
were followed between 1997 and 2002. Costs included antiretroviral therapies (ART), hospital admissions, prophylaxis, and
main laboratory examinations. The perspective was that of the National Health Service.
Results: Admission costs per person-year decreased from 2148 euro in 1997 to 256 in 2002, while the average annual costs of
ART increased from 2145 to 3149 euro (1997 prices). From 1997 to1999, ART costs increased from 42.3 to 85.9% of the total,
while admission costs decreased from 42.3 to 7.0% and prophylaxis from 7.3 to 1.7%. The breakdown of ART costs shows how
dual therapies decreased over time in favor of HAART, falling from 26.8% in 1997 to 5.9% in 2002. Patients with fewer than
five treatment switches had the lowest costs distributions over the entire observation period.
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Conclusions: From 1997 to 2002 inpatient costs progressively decreased in favor of antiretroviral therapy. Annual average costs
per patient decreased, while total direct costs increased over time: health resources, initially concentrated on hospitalized patients
were then distributed over a growing number of subjects.
© 2005 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
Since 1996, the use of powerful drug combinations
to treat HIV/AIDS has become widespread in Western
countries. Combinations of at least three different
antiretroviral molecules, belonging to the class of
nucleoside reverse transcriptase inhibitors (NRTI),
protease inhibitors (PI), or non-nucleoside reverse
transcriptase inhibitors (NNRTI), called HAART
(Highly Active Antiretroviral Therapy), have radically
changed the natural course of the HIV infection, as
has been widely recognized in the clinical literature.
Their theoretical efficacy in reducing the incidence
of new AIDS cases and associated mortality, shown
in controlled clinical studies [1,2], has since been
confirmed in the population [3–6]. As a consequence,
there has been a change in the use of health resources
for HIV positive patients from inpatient to outpatient
care, and from the use of drugs to treat opportunistic
in the I.CO.N.A. cohort study (Italian Cohort Naive
Antiretrovirals).
2. Methods
2.1. General characteristics of the I.CO.N.A. study
The present study considered 5422 patients from
the I.CO.N.A. cohort, enrolled between February 1997
and December 2002 in 69 Infectious Diseases Clinics.
I.CO.N.A. is an observational study that includes adult
patients with HIV infection naive to antiretrovirals
(ARVs). Clinical and epidemiological details of the
study have already been reported elsewhere [10]. The
following is a partial list of data collected at enrollment:
sex, age, risk factors for HIV infection, reasons for
being antiretroviral naive, employment status, date and
diagnosis of HIV-related and non HIV-related illnesses,
Centers for Disease Control classification, CD4+ lym-infections to antiviral medications [7–9].
The elevated cost of HAART, however, makes it im-
portant to investigate the impact of these combined
therapies also in terms of the composition and total
health expenses for the treatment of HIV/AIDS. Un-
fortunately, it is rather complex to determine with the
phocytes count and plasma HIV-RNA copies. The
following data are then collected during the study:
start and end dates of consecutive antiretroviral drug
regimens and reasons for discontinuation; start and
end date of prophylaxis and therapies for opportunistic
infections; hospital admissions and death.necessary precision the financial burden and the clini-
cal advantages associated with a single molecule of the
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2.2. Evaluation of costs
Prospective routine data collection does not include
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Pombination administered. In addition, various health
onditions and stages of the infection in patients at
he start of treatment make the prescribed course of
reatment notably different, therefore, it is preferable
n an analysis such as this to concentrate on evalu-
ting the costs of the drug combinations prescribed,
nd on the entire course of therapy for the individual.
aking these considerations into account, the objective
f the present work is to describe the trend of direct
ealth costs of HIV care in Italy after the introduction
f HAART by examining the evolution of these costsnformation on health costs. The present work evalu-
ted retrospectively costs incurred by the Italian Na-
ional Health Service (SSN) for hospital admissions,
rugs (antiretroviral, or for prophylaxis and treatment
f opportunistic infections) and major laboratory ex-
minations; all costs are expressed in euro.
The costs of antiretroviral therapies were cal-
ulated based on prices from the Italian National
harmaceutical Formulary, adjusting for the average
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discount given at hospitals in the period of observation
(varying between 27 and 55%, according to the com-
mercial product and the year considered). The average
daily cost of each drug was calculated based on the
daily dose usually administered, given standard dosage
and number of tablets/capsules in each package. The
average daily cost of the various drug combinations,
calculated as the sum of each individual drug cost,
was adjusted for variations in standard dosages in the
presence of particular drug combinations, and then
weighted for the total number of days of treatment in
each year. The duration of each therapy was rounded
up to the closest whole number of months, considering
that the cost for the entire package of medications
(usually corresponding to a month of treatment) is
covered by SSN, even when therapy is interrupted
early. Finally, annual cost of therapy per patient-year
was reported. The costs of antiretroviral therapy are ex-
pressed both in current prices and in 1997 prices when
compared to the other expenses categories. Prices
were deflated using the general Consumer Price Index.
The costs of inpatient admissions were recovered
applying national reimbursement rates [11], after link-
ing the appropriate Diagnosis Related Group (DRG)
to each admission on the basis of the discharge report,
and considering inpatient length of stay. Annual cost
of admissions was reported per person-year based on
the entire cohort population.
Likewise, for immunological and virological
examinations (lymphocytes subsets and viral load
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reported in the study. Finally, the annual cost of
prophylaxis per person-year was reported based on
the entire cohort population.
2.3. Statistical analysis
The data refer to the period from February 1997
to December 2002. The trend of AIDS defining events
(ADEs) and deaths was measured using the annual inci-
dence rate (the number of cases for total person-years
of the population followed in the year in question).
The cumulative probability to discontinue the first, sec-
ond, and following antiretroviral drug combinations
was calculated using the Kaplan–Meyer method. Dura-
tions of antiretroviral therapies by number of treatment
switches were compared using the log-rank test, which
allows the statistical significance of differences to be
evaluated. Distributions of antiretroviral therapies du-
rations were compared in a box-plot of the length of
treatments by number of switches.
3. Results
3.1. Clinical outcomes
The trend of mortality and ADEs per person-year in
the 5422 subjects enrolled between 1997 and 2002 in
the I.CO.N.A. cohort confirms the efficacy of HAART
in reducing morbidity and mortality from HIV infec-
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ossessment) we referred to the rates established by the
ational formulary for ambulatory assistance services
12].
The costs of prophylaxis were based on retail prices
rom the Italian National Pharmaceutical Formulary,
nd reported in 1997 prices. When a chemical entity
sed in prophylaxis corresponded to more than one
ommercial product (whether branded or generic
rugs) we used the price of the one with the highest
arket share. The daily average cost of each drug was
alculated based on the daily dose most commonly
rescribed, given the standard dosage and the number
f tablets/capsules per package. The average daily
ost was then weighted for the total number of
reatment days for each year. In many cases the date of
reatment completion was missing for prophylaxis and
reatments for opportunistic infections; we substituted
ith the average duration of the same type of therapiesion (Fig. 1). From 1997 to 2002 the number of ADEs
er person-year in the I.CO.N.A. cohort decreased from
06 to 26 per thousand, and the number of deaths per
erson year from 29 to 8 per thousand. The incidence
f hospital admissions in the cohort also decreased dra-
atically from 26.4 per thousand person-years in 1997
o 7.8 per thousand in 1998, revealing values even lower
han five per thousand from 1999 on. Similarly, length
f stay drastically decreased from an annual average of
.6 days per patient in 1997 to 0.9 days in 2002.
.2. Antiretroviral therapies
There were 3641 (67.2%) patients in the cohort who
ollowed at least one antiretroviral regimen between
997 and 2002. No significant difference was found
etween the estimated duration of the first and sec-
nd therapy, but the difference was significant between
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Fig. 1. Number of deaths, Aids defining events, and hospital admis-
sions per person-year (95% CIs).
the first two therapies compared with salvage therapies
(median: 14 versus 11 months, p < 0.0001). A box-plot
of the duration, in months, of antiretroviral therapies
by treatment switch is reported in Fig. 2.
The patients who followed few therapies (maximum
four switches in 6 years) show the lowest costs distri-
butions over the entire observation period (standard-
ized for the greater level of persistence of initial drug
combinations); more atypical combinations, with much
higher average annual costs, were seen in patients who
received more therapies (Table 1).
Based on the frequency of each drug combination,
characterized by number and class of molecules in
Fig. 2. Box-plot of therapy duration by treatment switch.
the mix, 13 common pharmacological combinations
and one residual were identified. Table 2 reports the
frequency (in percentages) of these drug mixes in
total therapies started each year and Fig. 3 shows
percentage costs of prevalent combinations over the
6 year period. Data reveals that the weight of dual
therapies, still very common at the beginning of the
study period, decreased over time both in terms of
frequencies and costs in favor of HAART. From
2000, more diversified triple therapies were observed
(corresponding to the introduction of new anti-HIV
molecules to the market). In recent years, an increase in
the incidence of so-called mega-HAART and atypical
Table 1
Average costs (euro) of antiretroviral therapy by number of treatment switches
Number of
treatment switches
Number of
patients
Average
cost 1997
Average
cost 1998
Average
cost 1999
Average
cost 2000
Average
cost 2001
Average
cost 2002
1 1498 4914 5324 5528 5742 5923 6246
2 882 5194 5579 5879 6066 6218 6237
3 594 5201 5776 6201 6272 6331 6350
4 325 5274 6004 6404 6551 6610 6724
5 162 5568 6183 6694 6732 6796 6970
6 89 5214 6143 6629 6680 6978 7327
7 38 6296 6025 7072 7264 7216 7009
8 22 5629 6394 6530 6668 6970 8153
9 16 5015 6110 7079 7356 7076 7112
10 8 4832 6759 6355 6876 6986 6745
11 1 2996 5840 8757 7810 9666 8806
12 3 2996 6939 6546 5655 6358 8278
13 2 7345 7798 7403 5935 6683 9616
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Table 2
Frequencies (percentages) of main antiretroviral regimens
Antiretroviral regimens
that include
1997 1998 1999 2000 2001 2002
1NRTIa 1.6 1.6 0.8 0.8 0.4 0.5
1NRTI + 1NNRTIb 0.0 0.1 0.7 0.5 0.4 0.8
1NRTI + 1NNRTI + 1PIc 0.0 0.8 2.4 0.9 0.4 0.3
1NRTI + 1PI 1.8 1.9 1.6 0.2 0.3 0.1
1NRTI + 2PI 0.1 0.7 0.9 0.5 0.8 0.8
2NRTI 39.6 21.2 13.0 7.8 7.8 6.1
2NRTI + 2PI 0.3 2.6 2.4 7.1 14.4 21.3
2NRTI + NNRTI 0.1 8.5 27.3 45.4 41.0 31.9
2NRTI + NNRTI + PI 0.0 0.3 1.2 0.8 1.1 0.5
2NRTI + PI 55.7 61.0 46.3 27.4 14.8 14.6
3NRTI 0.3 0.2 1.0 4.3 15.0 17.0
3NRTI + NNRTI 0.0 0.0 0.1 0.7 0.6 1.6
3NRTI + PI 0.3 0.0 0.2 0.2 0.4 0.1
Other 0.3 1.0 2.0 3.2 2.8 4.3
Patients without ART (%) 58.8 51.9 50.3 49.3 48.5 45.6
a NRTI: nucleoside reverse transcriptase inhibitor.
b NNRTI: nonnucleoside reverse transcriptase inhibitor.
c PI: protease inhibitor.
drug combinations has been reported. Data relative
to 2 NRTIs and 2 PIs combinations instead reflect the
spread of therapies with 2 PIs used in association.
Average costs per patient-year of prevalent an-
tiretroviral therapies remained relatively stable over
time, due to scarce price variations of the commercial
products. In 2002 annual average costs per patient (that
is, costs per patient-year taking ARVs) were 3520 euro
for dual therapy, 6051 for HAART with one NNRTI,
Fig. 3. Percentage incidence on total costs of prevalent antiretroviral
therapies. NRTI: nucleoside reverse transcriptase inhibitor, NNRTI:
nonnucleoside reverse transcriptase inhibitor, PI: protease inhibitor.
“Other” refers exclusively to the drug combination defined as resid-
ual.
6474 for therapies with three NRTIs, 7299 for HAART
with one PI, and 7634 for therapies with two PIs. The
above costs include the 5% reduction in drug prices set
forth by the government in April 2002. The data show
however that total costs of ART per person-year (treated
or not with antiretroviral medications) increased from
2145 euro in 1997 to 3149 euro in 2002 (1997 prices),
testifying the passage from early therapies to increas-
ingly more powerful and expensive combinations. The
percentage of ART patients on total person-years in
the cohort ranged from 40.9% in 1997 to 66.7% in
2000.
Average cost difference among first, second and suc-
cessive therapies decreased over time from 403 euro in
1998 (in 1997 the number of therapies from the third
switch on was still too small to obtain a stable average)
to 134 euro in 2001 (differences between costs increase
again to 323 euro in 2002). Even if higher on average,
costs of salvage therapies decreased over time, reach-
ing levels of the first two therapeutic lines (from an
average of 7315 euro in 1998 to 6903 euro in 2002).
The average cost of second HAART decreased from
6974 euro in 1997 to 6609 in 2002, and since 2001 has
been even lower than the average cost of first HAART,
following the tendency to simplify antiretroviral com-
binations towards maintenance therapy in patients for
whom the first therapy was effective.
The average annual costs of the remaining therapies
(non HAART) increased slightly from 3215 euro per
patient-year in 1997 to 3537 euro in 2002.
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fCosts per person-year not under ART increased
rom 2431 euro in1997 to 2793 in 2000 and then de-
reased again to 1904 euro in 2002. This last figure
ay be lower than average also because patients who
ere not reported as dropped before December 31,
002 were considered still in follow-up until the end
f the observation period, and drop-outs are recorded
ith some delay among patients without ART.
.3. Hospital admissions
About 20% of patients had at least one hospital
dmission (15% had a single admission, and 3%
wo). In the univariate analysis, factors positively
orrelated to at least one admission were disease stage
t enrollment and number of HIV and non-HIV related
llnesses. Inpatient costs per person-year drastically
ell after the spread of HAART in 1998, and continued
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to drop almost monotonically in the following years,
decreasing from 2148 euro in 1997 to 256 euro in 2002.
In subjects treated with HAART, average inpatient
costs decreased from 345 euro per year in 1997 to 205
in 2002. It is evident how the increasingly widespread
use of HAART was the fundamental cause in reducing
inpatient costs in the whole cohort.
3.4. Therapies for opportunistic infections
The costs of prophylaxis and treatments for oppor-
tunistic infections per person-year decreased from 371
euro in 1997 to 26 euro in 2002 (−93%); the greatest
reduction was found between 1997 and 1999 (−80%).
The composition of costs for opportunistic infections
treatment remained similar over time, with a prevalence
of herpetic viruses (on average 37% of the total), fol-
lowed by mycosis (31%) and mycobacteria (27%); the
costs for PCP (Pneumocisti Carinii Pneumonia) and
toxoplasmosis were residuals.
3.5. Laboratory examinations
Laboratory expenses decreased almost constantly
over the 6 years of observation from 409 euro in
1997, to 218 euro in 2002. In particular, costs for lym-
phocytes subsets decreased monotonically over time,
falling from 81 to 42 euro per year between 1997 and
2002. In all, the costs for HIV-RNA decreased from
328 euro in 1997 to 176 in 2002 (showing a strong
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which they increased, to 4581 euro in 2000, and
decreased again to 3649 in 2002. The incidence of
hospital admissions, antiretroviral therapies, prophy-
laxis and treatments of opportunistic infections, and
immunological and virological examinations on total
costs changed markedly over time. In less than 2 years
(from 1997 to 1999), costs for ART increased from
42.3 to 85.9% of the total, while costs for admissions
decreased from 42.3 to 7.0%; costs of prophylaxis and
laboratory examinations changed from 7.3 and 8.1%
in 1997 to 0.7% and 6.0% in 2002, respectively.
4. Discussion
The I.CO.N.A. study collects prospective data com-
ing from over 70 clinical centers in Italy that follow
about 65% of the known HIV-positive population [13].
As already detailed in previous analyses, carried out in
this [14] and other Italian studies [6,15–17], the diffu-
sion from 1996 of antiretroviral combination therapies
with three or more drugs (HAART) led to a marked
decrease in mortality and incidence of AIDS cases.
This trend certainly led to a notable change in health
costs. There are not many Italian studies on health re-
sources consumption and costs of HIV-positive patients
after the diffusion of HAART. A study conducted on
181 patients with less than 200 CD4/mm3 estimated
that the average length of inpatient stays decreased
from 18.9 days per person-year in 1996 to 15.6 in 1997,
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Aownturn at the beginning: −33% between 1997 and
998). In particular, the costs for laboratory examina-
ions followed the same trend between first, second, and
uccessive antiretroviral therapies; patients with three
r more switches incurred the highest expenses (the dif-
erence in laboratory costs between patients in first line
herapy and patients with at least three switches was
6 euro in 2002). The downward trend of laboratory
xpenses is due to the steady decrease in the average
umber of tests performed. In 1997, lymphocytes sub-
ets and HIV-RNA assessments per person-year were
.7 and 4.2, respectively, whereas by 2002 they had
iminished to 2.4 and 2.3, respectively.
.6. Total costs
Total costs per person-year in the cohort decreased
rom 5073 euro in 1997 to 4226 in 1998; followingollowing a 70% reduction in new ADEs and a steady
ecrease in mortality. Total expenses remained similar
n the 2 years considered, but moved from inpatient
osts, to antiretroviral medications expenses [18]. A
ater multicenter observational study, with 483 patients
ollowed from 1997 to 1998, reported a shorter length
f stay (8.7 days per person-year) compared to previ-
usly published results, but similar to the estimates ob-
ained in the present study, and ascribed this finding to
wider diffusion of HAART. The same study recorded
RT costs per patient-year ranging from 1885 euro for
symptomatic subjects with more than 500 CD4/mm3
o 5353 euro for symptomatic patients [19]. In a recent
tudy that retrospectively compared data of a cohort of
ymptomatic patients in 1994 with a similar cohort in
998, a reduction of 3925 euro (1999 prices) in direct
ealth costs per person-year was calculated. In 1998,
RT costs per patient-year were equal to 7283 euro
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and accounted for 63.5% of total direct medical costs
[20].
From the present study it emerges that, although
expenses related to antiviral therapies increased by
34% per person-year, from 1997 to 2002 inpatient
costs for HIV-positive patients noticeably decreased
(88%) in Italy. In particular, costs of hospital admis-
sions per person-year were always inferior (20%) in
the population treated with HAART. HAART therapy
permanently modified health resources consumption,
moving it from the hospital to the patient’s home:
the observed reduction in inpatient expenses was the
consequence of a lower incidence of ADEs and other
opportunistic infections. In addition, the study shows
that with the emergence of diagnostic standards for the
new antiretroviral therapies, laboratory examinations
costs decreased by 47% in 6 years. Paralleling the
improvement in immuno-virologic parameters and
clinical conditions of patients in the cohort is the
almost complete disappearance, in terms of incidence
on total costs, of prophylactic therapies and treatments
for opportunistic diseases (−93%).
It is difficult to compare such results with those
obtained in other countries, due to the differences in
the epidemiology of the HIV infection and of struc-
tural differences between health systems, in terms of
type of health services offered and their accessibility,
as well as health resources consumption implied. In a
prospective, monocentric study on direct health costs in
a German cohort of 201 HIV-positive patients enrolled
i
m
i
r
t
d
e
[
c
l
t
p
f
c
l
fi
f
t
America that received assistance in 1996. As a result
of the introduction of HAART, total cost per patient
decreased by 10% between 1996 and 1998 [9].
The costs of antiretroviral therapy computed in our
work are in line with those reported by previous Italian
studies, but notably lower than those found by other
European and US researches. Since ARVs are covered
by the SSN only if delivered at hospital, we valued
antiretroviral drugs at hospital prices, which can be
even less than half of retail prices (hospital prices were
also used by other Italian studies [19,20]). In addition,
the I.CO.N.A. cohort enrolls subjects who are still naive
to ARVs. These patients are often in earlier stages of the
disease and receive less expensive treatments compared
to those included in many published works.
The introduction in Italy starting from 1995 of
DRGs as the basis of a prospective reimbursement sys-
tem for hospital services raised several issues at the be-
ginning [22]. It was necessary to adopt a coding system
for procedures and to produce a minimum discharge set
for each acute care hospital stay. Major difficulties in
the implementation of DRGs concerned lack of reli-
able information on production costs and of case-mix
statistics. As a result, the compensation rates as to some
DRGs provide an opportunity for profit, while the com-
pensation rates for other DRGs do not cover the actual
costs of providing those services. So far there has not
been a specific debate on the adequacy of compensation
rates for HIV care, whereas some concerns have arisen
about the possible misclassification of cases. Some in-
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sn 1997, and with follow-up visits in 2000 and 2001,
ean HAART costs per patient-year decreased signif-
cantly from 17,746 to 16,007 euro. Together with the
eduction of expenditures for additional drugs, hospi-
al admissions and diagnostic tests, this led to a 32%
ecrease of total direct costs, from a mean of 35,865
uro per patient-year in 1997 to 24,482 euro in 2001
21]. Another study, conducted on an observational
ohort of Medicaid patients in Maryland (USA) fol-
owed between 1995 and 1997, similarly concluded
hat a PI containing regimen significantly reduced in-
atient costs and expenses related to opportunistic in-
ections, so that even if pharmaceutical expenses in-
reased, overall health costs remained stable or slightly
ower for these patients [8]. This tendency was con-
rmed by the HIV Cost and Services Utilization Study,
or which 2864 patients were interviewed, represen-
ative of the entire HIV-positive adult population inatient episodes regarding HIV positive subjects may
e improperly assigned to Major Diagnostic Category
MDC) 25-HIV infection so as to benefit of the higher
eimbursement rates for DRGs that fall under this di-
gnostic category.
The present study has some limitations. In the
rst place, the perspective was that of the SSN:
hus, direct non-health costs (various out of pocket
xpenses, such as transportation) were not taken into
onsideration nor indirect costs associated to patients’
roductivity losses. Ignoring indirect costs may have
nderestimated the potential benefits of HAART.
econdly, the analysis did not include all health costs.
t was impossible, for example, to distinguish visits
o a specialist in an infectious diseases ward from
ay-hospital admissions; in addition, data on resis-
ance tests were incomplete, and consultations with
pecialists from other wards were missing. Moreover,
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standard costs were used for the evaluation of hospital
services (national DRGs rates). In theory, unit costs
of hospital resources should instead be estimated
based on a detailed examination of costs involving all
hospitals participating in the study. The reimbursement
rates might not accurately reflect real costs of HIV
hospital care. Another limitation concerns the repre-
sentativeness of the I.CO.N.A. cohort with respect to
the adult HIV-positive population in Italy: in the first
phase of enrollment above all, subjects in advanced
phases of the infection, who, for whatever reason,
had not yet been treated with antiretroviral drugs
were over-represented in the sample. Finally, there
is a problem in the cohort of temporary interruptions
of follow-up: in these cases it is not usually possible
to combine the separate treatment periods occurred
at one or more participating hospitals. The date of
administrative censoring was December 31, 2002, for
all patients not lost to follow-up for any reason before
that date (independently of the date of their last visit).
The present study is an analysis of the costs of HIV
infection, which does not take into consideration the
substantial clinical benefits of HAART, in terms of
improvements in expected length and quality of life.
We tried to retrospectively reconstruct the direct costs
following a bottom-up approach, meaning estimating
total health expenses from resources consumption data
collected at the patient level; then, discounted costs,
standardized for unit of time, and composition of total
costs per expense category were calculated [23]. Full
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determinants of the high costs of treatment and
hospitalizations associated to specific patient profiles.
5. Conclusions
Despite the above limitations, this study provided
important information on the costs of HIV patients
management in Italy, due to the size of the observa-
tional sample considered, and the detailed information
available, especially on antiretroviral therapies. Con-
sistently with the recent international literature, the re-
sults of the analysis testified the change in the compo-
sition of expenses, characterized by the progressive re-
duction in inpatient costs in favor of antiretroviral ther-
apy. Annual average costs per patient decreased: the
reduction in the incidence of hospital admissions, com-
bined with the administrative reduction in the prices of
medications in 2002, offset the spread of more expen-
sive antiretroviral therapies. Total direct costs instead
seemed to increase over time, as a consequence of the
fact that more patients were permanently treated and
continued antiretroviral therapy for longer and longer
periods of time. As a result of this trend, health re-
sources first concentrated essentially only on hospi-
talized patients, were then distributed over a growing
number of patients.
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Dconomic analyses [24] like those that compare costs
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erms of costs and outcomes of important clinical
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ppendix A
The members of the I.CO.N.A. Study Group are:
taly: Ancona: M Montroni, G Scalise, MC Braschi,
S Del Prete. Aviano (PN): U Tirelli, R Cinelli. Bari:
Pastore, N Ladisa, G Minafra. Bergamo: F Suter,
Arici. Bologna: F Chiodo, V Colangeli, C Fiorini,
Coronado. Brescia: G Carosi, GP Cadeo, C Torti,
Minardi, D Bertelli. Busto Arsizio: G Rizzardini,
Migliorino. Cagliari: PE Manconi, P Piano. Catan-
aro: T Ferraro, A Scerbo. Chieti: E Pizzigallo, M
’Alessandro. Como: D Santoro, L Pusterla. Cremona:
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